Clinical Trial Update: Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for Palomid 529 in neovascular age-related macular degeneration. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Palomid 529

Snippet

Sponsor: National Eye Institute (NEI) | Conditions: Age-Related Macular Degeneration | Phase 1 | Status: COMPLETED